Advanced Breast Cancer Patients Denied Access To Breakthrough Treatment
 

National Institute for Health and Clinical Excellence (NICE) issues negative draft decision for Afinitor® (everolimus) The National Institute for Health and Clinical Excellence (NICE) today issued an Appraisal Consultation Document (ACD) recommending that Novartis' life extending advanced breast cancer treatment, Afinitor® (everolimus), should not be available to patients on the NHS...

More...